KYMR
HealthcareKymera Therapeutics, Inc.
$72.41
$-0.35 (-0.48%)
Jan 5, 2026
Price History (1Y)
Analysis
Kymera Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $5.79 billion and approximately 225 employees. It generates revenue through various business activities, although specific details about its products or services are not provided. Financially, Kymera has reported negative net income and EBITDA of $-295 million and $-321 million respectively in the trailing twelve months (TTM). Its gross margin is at 0%, operating margin is -3207.9%, and profit margin is also at 0%. The company's return on equity (ROE) is -32.1% and return on assets (ROA) is -19.2%. Kymera has a debt-to-equity ratio of 8.88 and $84 million in debt, while its cash balance stands at $505.68 million. The valuation context for Kymera Therapeutics includes a forward price-to-earnings (P/E) ratio of -19.53, which is negative. The company's revenue growth rate is -26.1% year-over-year (YoY), but earnings growth data is not available. Dividend yield and payout ratio are both N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $5.79B
- P/E Ratio
- N/A
- 52-Week High
- $103.00
- 52-Week Low
- $19.45
- Avg Volume
- 943.07K
- Beta
- 2.22
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 225